Jeerunda Santiprabhob

Dr. Jeerunda Santiprabhob

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Gene
Verified
Journal Article
Closed access
WTWatip Tangjittipokin
Watip Tangjittipokin
PUPichakorn Umjai
Pichakorn Umjai
KKKhwanhatai Khemaprasit
Khwanhatai Khemaprasit
PCParichat Charoentawornpanich
Parichat Charoentawornpanich
CCChutima Chanprasert
Chutima Chanprasert
JSJeerunda Santiprabhob
Jeerunda Santiprabhob

19 August 2020 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
PDPrapai Dejkhamron
Prapai Dejkhamron
JSJeerunda Santiprabhob
Jeerunda Santiprabhob
SLSupawadee Likitmaskul
Supawadee Likitmaskul
CDChaicharn Deerochanawong
Chaicharn Deerochanawong
PRPetch Rawdaree
Petch Rawdaree
WNWannee Nitiyanant
Wannee Nitiyanant
Aims/Introduction: The Thai Type 1 Diabetes and Diabetes Diagnosed Before Age 30 Years Registry, Care and Network was established in 2014 and involved 31 hospitals. The objective of the registry was to evaluate glycemic control and complications of patients with type 1 diabetes.Materials and Methods: Patients’ demographics, clinical data, frequencies of daily self‐monitoring of blood glucose (SMBG), glycemic control and complications were collected.Results: Among the 1,907 type 1 diabetes patients, the mean age was 21.2 ± 11.3 years. The mean glycated hemoglobin level was 9.35 ± 2.41%, with significant variations among age groups (P < 0.001). Conventional insulin treatment and intensive insulin treatment were used in 43 and 57% of patients, respectively. Mean glycated hemoglobin levels were significantly higher in patients treated with conventional insulin treatment compared to those treated with intensive insulin treatment (9.63 ± 2.34 vs 9.17 ± 2.46%, P = 0.002). Compared to the conventional insulin treatment group, significantly more patients in the intensive insulin treatment group achieved good glycemic control (P < 0.001), and fewer had diabetic retinopathy (P = 0.031). The prevalence of microvascular complications increased significantly with age (P < 0.001). Multivariate analysis showed good glycemic control to be associated with age 25 to <45 years, intensive insulin treatment with SMBG three or more times daily and diabetes duration of 1 to <5 years.Conclusions: Most Thai type 1 diabetes patients were not meeting the recommended glycemic target. As a result of this study, the national program to improve the quality of diabetes treatment and education has been implemented, and the results are ongoing.

10 December 2021 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
PDPrapai Dejkhamron
Prapai Dejkhamron
JSJeerunda Santiprabhob
Jeerunda Santiprabhob
SLSupawadee Likitmaskul
Supawadee Likitmaskul
CDChaicharn Deerochanawong
Chaicharn Deerochanawong
PRPetch Rawdaree
Petch Rawdaree
CRCare And Network (T1Ddar Cn) For The Thai Type 1 Diabetes And Diabetes Diagnosed Age Before 30 Years Registry
Care And Network (T1Ddar Cn) For The Thai Type 1 Diabetes And Diabetes Diagnosed Age Before 30 Years Registry
Aims/Introduction: There is a lack of current information regarding young‐onset diabetes in Thailand. Thus, the objectives of this study were to describe the types of diabetes, the clinical characteristics, the treatment regimens and achievement of glycemic control in Thai patients with young‐onset diabetes.Materials and Methods: Data of 2,844 patients with diabetes onset before 30 years‐of‐age were retrospectively reviewed from a diabetes registry comprising 31 hospitals in Thailand. Gestational diabetes was excluded.Results: Based on clinical criteria, type 1 diabetes was identified in 62.6% of patients, type 2 diabetes in 30.7%, neonatal diabetes in 0.8%, other monogenic diabetes in 1.7%, secondary diabetes in 3.0%, genetic syndromes associated with diabetes in 0.9% and other types of diabetes in 0.4%. Type 1 diabetes accounted for 72.3% of patients with age of onset <20 years. The proportion of type 2 diabetes was 61.0% of patients with age of onset from 20 to <30 years. Intensive insulin treatment was prescribed to 55.2% of type 1 diabetes patients. Oral antidiabetic agent alone was used in 50.8% of type 2 diabetes patients, whereas 44.1% received insulin treatment. Most monogenic diabetes, secondary diabetes and genetic syndromes associated with diabetes required insulin treatment. Achievement of glycemic control was identified in 12.4% of type 1 diabetes patients, 30% of type 2 diabetes patients, 36.4% of neonatal diabetes patients, 28.3% of other monogenic diabetes patients, 45.6% of secondary diabetes patients and 28% of genetic syndromes associated with diabetes patients.Conclusion: In this registry, type 1 diabetes remains the most common type and the prevalence of type 2 diabetes increases with age. The majority of patients did not achieve the glycemic target, especially type 1 diabetes patients.

1 March 2015 in Gene
Verified
Journal Article
Closed access
WCWanida Chuenta
Wanida Chuenta
BPBenjaluck Phonrat
Benjaluck Phonrat
ATAnchalee Tungtrongchitr
Anchalee Tungtrongchitr
CLChanin Limwongse
Chanin Limwongse
NCNalinee Chongviriyaphan
Nalinee Chongviriyaphan
RTRungsunn Tungtrongchitr
Rungsunn Tungtrongchitr

1 October 2014 in Patient Education and Counseling
Verified
Journal Article
Closed access
JSJeerunda Santiprabhob
Jeerunda Santiprabhob
CLChanin Leewanun
Chanin Leewanun
KLKawewan Limprayoon
Kawewan Limprayoon
PKPornpimol Kiattisakthavee
Pornpimol Kiattisakthavee
RWRenu Wongarn
Renu Wongarn
SLSupawadee Likitmaskul
Supawadee Likitmaskul

2 June 2018 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
JSJeerunda Santiprabhob
Jeerunda Santiprabhob
KLKawewan Limprayoon
Kawewan Limprayoon
PAPrapun Aanpreung
Prapun Aanpreung
RCRatiya Charoensakdi
Ratiya Charoensakdi
RKRuchaneekorn W. Kalpravidh
Ruchaneekorn W. Kalpravidh
RTRungsunn Tungtrongchitr
Rungsunn Tungtrongchitr
Background: Dysregulation of adipocytokines, inflammatory cytokines and oxidative stress are associated with the pathogenesis of obesity-related complications. This study aimed to evaluate the effect of a group-based lifestyle modification program on adipocytokines, inflammatory cytokines, oxidative status and arterial stiffness in obese youth. Methods: A 1-year weight-reduction program was conducted. The program consisted of initial hospitalization and five outpatient group-based sessions held at 1, 2, 3, 6 and 9 months. Pre-and post-intervention measurements included anthropometric data, blood tests, body composition and brachial-ankle pulse wave velocity (ba-PWV). Results: A total of 126 obese youths were recruited, and 115 of those completed the study. Twenty-four participants had increased percentage weight for height at the end of the study (group A), 30 had minimal reduction (group B) and 61 had substantial reduction (group C). Lean mass significantly increased in all three groups (all p < 0.001). A significant decrease in leptin (group A, p = 0.021; group B, p = 0.005; group C, p < 0.001), interleukin-6 (IL-6) (group A, p = 0.019; group B, p = 0.004; group C, p < 0.001) and ba-PWV (group A, p = 0.031; group B, p = 0.015; group C, p < 0.001) was also observed. No significant change in the oxidative status was found among the groups. Reduction in ba-PWV was correlated with decreases in plasma malondialdehyde (pMDA) (r = 0.233, p = 0.036) and home-ostasis model assessment of insulin resistance (HOMA-IR) (r = 0.253, p = 0.025). Conclusions: A group-based healthy lifestyle program for obese youths had beneficial effects on adipocytokines, inflammatory cytokines and arterial stiffness. Participants without change in weight status also benefited. These improvements may reduce the risk of obese youths developing atherosclerosis.